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Abstract
Granulocyte-colony stimulating factor (G-CSF) has been shown to promote mobilization of bone marrow-derived stem cells (BMCs) into
the bloodstream associated with improved survival and cardiac function after myocardial infarction. Therefore, the aim of the present
study was to investigate whether G-CSF is able to attenuate cardiac remodelling in a mouse model of pressure-induced LV hypertro-
phy focusing on mobilization and migration of BMCs. LV hypertrophy was induced by transverse aortic constriction (TAC) in C57BL/6J
mice. Four weeks after TAC procedure. Mice were treated with G-CSF (100 lg/kg/day; Amgen Biologicals) for 2 weeks. The number of
migrated BMCs in the heart was analysed by flow cytometry. mRNA expression and protein level of different growth factors in the
myocardium were investigated by RT-PCR and ELISA. Functional analyses assessed by echocardiography and immunohistochemical
analysis were performed 8 weeks after TAC procedure. G-CSF-treated animals revealed enhanced homing of VLA-4+ and c-kit+ BMCs
associated with increased mRNA expression and protein level of the corresponding homing factors Vascular cell adhesion protein 1
and Stem cell factor in the hypertrophic myocardium. Functionally, G-CSF significantly preserved LV function after TAC procedure,
which was associated with a significantly reduced area of fibrosis compared to control animals. Furthermore, G-CSF-treated animals
revealed a significant improvement of survival after TAC procedure. In summary, G-CSF treatment preserves cardiac function and is
able to diminish cardiac fibrosis after induction of LV hypertrophy associated with increased homing of VLA-4+ and c-kit+ BMCs and
enhanced expression of their respective homing factors VCAM-1 and SCF.
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Introduction
LV hypertrophy accompanied by interstitial myocardial fibrosis is one
of the main reasons for heart failure in patients with arterial hyperten-
sion and aortic stenosis (AS) [1]. Moreover, it has been shown that
cardiac fibrosis is an important morphological substrate of postoper-
ative clinical outcome in patients with severe AS and is not completely
reversible after aortic valve replacement [2]. No medical therapies are
particularly effective for retarding and reversing this maladaptive
remodelling in patients with LV hypertrophy [3]. Therefore, there is a
great interest in new strategies to qualitatively and quantitatively alter
collagen production and turnover, as well as to modify different extra-
cellular matrix (ECM) components, which are crucial in mediating
myocardial hypertrophy and fibrosis [4].
In the last years, regeneration of ischaemic myocardial tissue has
been attempted using bone marrow-derived stem cells (BMCs) and
pluripotent stem cells [5, 6]. As an alternative to the direct intramyo-
cardial injection [7, 8], mobilization of BMCs using growth factors,
such as the hematopoietic cytokine granulocyte-colony stimulating
factor (G-CSF), have been successfully utilized [9–11]. Migration of
circulating mobilized BMCs from the bloodstream into the damaged
tissue is suggested to play a key role for tissue regeneration [12]. The
interaction of stromal cell-derived factor-1 (SDF-1/CXCL12) with its
ligand chemokine receptor type 4 (CXCR4) on mobilized hematopoi-
etic progenitor cells has been shown to play a major role in migration
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of BMCs into ischaemic myocardium [11, 13]. G-CSF administration
after acute myocardial infarction (MI) resulted in diminished stem cell
homing caused by the N-terminal cleavage of SDF1 [14] and this
could be one explanation for the poor clinical results of patients trea-
ted with G-CSF post MI [15]. However, in non-ischaemic cardiomyop-
athy the interaction of SDF-1 with CXCR4 seems not to be involved in
a cardiac self-repair mechanism, because cardiac SDF-1 expression
was not up-regulated in dilated cardiomyopathy (DCM) hearts of
humans [16].
There is first evidence that G-CSF might be a promising therapeu-
tic agent to treat congestive heart failure because of cardiac hypertro-
phy and fibrosis. Szardien et al. were able to demonstrate that G-CSF
leads to the regression of myocardial fibrosis and improves cardiac
function after pressure unloading in mice [17]. However, the exact
mechanisms of fibrosis regression after G-CSF treatment are still
unclear.
Therefore, the aim of our study was to investigate whether G-CSF
is able to attenuate cardiac hypertrophy and fibrosis in a mouse
model of pressure-induced LV hypertrophy induced by transverse
aortic constriction (TAC). Moreover, we wanted to exploit whether
and how G-CSF is facilitating enhanced migration of BMCs after TAC
procedure. To avoid impairing the cellular setting of this hypertrophy
model and to ensure all findings are caused by the treatment only, we
did not perform pressure unloading.
Material and methods
Animal model
As a model for pressure-induced LV hypertrophy, C57Bl/6 wild-type mice
(Charles River Laboratories, Sulzbach, Germany) were subjected to TAC.
All mice used in this study were 8–10 weeks old healthy males. Mice were
anesthetized by an intra-peritoneal (i.p.) injection of a mixture of
Medetomidine (Domitor, Pfizer, Berlin, Germany), Midazolam (Midazolam
ratiopharm, Ratiopharm, Ulm, Germany) and Fentanyl (Fentanyl-
Janssen, Janssen-Cilag, Neuss, Germany). Mice were placed in supine
position on a heating pad and temperature was maintained at 37°C. For
the surgical procedure mice were intubated, and artificially ventilated by a
mouse ventilator (MiniVent, HUGO SACHS, March, Germany) with 200
strokes/min. and 200 ll/stroke. A short skin cut longitudinal to the ster-
num was followed by a 3–4 mm long sectioning of the cranial sternum.
The thymus lobes were separated and secured by two retractors, giving a
free view of the aortic arch. Between the right brachiocephalic artery and
the left common carotid artery, the transverse aorta was carefully mobi-
lized by forceps, allowing to navigate a silk thread (6-0 polypropylene
suture) behind the aorta. For constriction, a 27-gauge needle was placed
between transverse aorta and silk thread before instrument tying. The
removal of the needle ensured a standardized diameter of 0.4 mm of the
transverse aorta. The sternum was adapted with a 5-0 polypropylene
suture. The skin was closed with a 5-0 silk suture and mice were allowed
to recover from anaesthesia on the heating pad. Animal care and all exper-
imental procedures were performed in strict accordance to the German
and National Institutes of Health animal legislation guidelines and were
approved by the local animal care committees (Regierung von Oberbay-
ern). The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
Administration of G-CSF
4 weeks after TAC procedure, mice were randomly divided into the fol-
lowing groups, each treated for 2 weeks, receiving five injections per
week: (i) subcutaneous administration of saline (0.9% NaCl) and (ii)
administration of G-CSF (100 lg/kg/day; Amgen Biologicals, Thousand
Oaks, CA, USA).
Flow cytometry of non-myocyte cardiac cells
For analysis of BMCs within the hearts, a ‘myocyte-depleted’ cardiac cell
population was prepared, incubating minced myocardium in 0.1% colla-
genase IV (GIBCO BrL, Carlsbad, CA, USA) 30 min. at 37°C, lethal to most
adult mouse CMs. Cells were then filtered through a 70 mm mesh. To
exclude spurious effects of enzymatic digestion, BM cells with or without
collagenase treatment were stained revealing no significantly changed
staining of labelled cell antigens. Mononuclear cells were separated by
density-gradient centrifugation using 1.077 g/ml Histopaque solution
(Sigma Chemicals, St. Louis, MO, USA), purified, and resuspended in PBS
containing 1% BSA. Cells were incubated for 40 min. in the dark at 4°C
with the following fluoresceinisothiocyanate (FITC), phycoerythrin (PE)
and peridininchlorophyll-protein (PerCP) conjugated monoclonal antibod-
ies: CD45-PerCP, CD34-FITC, VLA-4-PE, c-kit-PE and CXCR4-PE (all from
BD Pharmingen). Matching isotype antibodies (BD Pharmingen, San Jose,
CA, USA) served as controls. Cells were analysed by three-colour flow
cytometry using a Coulter EpicsXL-MCLTM flow cytometer (Beckman
Coulter, Cincinnati, OH, USA). Each analysis included 50.000 events.
Quantitative RT-PCR and ELISA
Hearts were explanted and the LVs were separated. Isolation of total RNA
from mouse heart tissue was performed with TRI REAGENT (Molecular
Research Center, Inc., Cincinnati, OH, USA) according to the manufacturer’s
protocol. Reverse transcription was performed with the ImProm-IITM
Reverse Transcription System (Promega, Fitchburg, WI, USA) according to
the manufacturer’s protocol. cDNA samples were analysed by quantitative
RT-PCR using adequate murine primers purchased fromMWG-BIOTECH AG,
Ebersberg, Germany. Quantitative RT-PCR was performed with SYBR Green
Reaction Mix (Eurogentec, Cologne, Germany) on an ABI PRISM 7900HT
Detection System (Applied Biosystems, Carlsbad, Germany). Each sample
was run in duplicate. The expression of each gene within the different tissue
samples was quantified relative to H4 mRNA expression levels according to
the Sequence Detector User Bulletin (Applied Biosystems).
VCAM-1 and SCF protein levels were quantified using commercially
available kits (R&D Systems, Minneapolis, MN) according to the manufac-
turer’s instructions.
Histopathology
8 weeks after the TAC procedure, hypertrophic hearts were extracted after
perfusion fixation via blood flow. Before punctuating the right ventricle,
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hepatic veins were cut. First, the hearts were cleaned from blood with
PBS buffer for 1 min. Then perfusion fixation started with formalin (4%)
for 5 min. After carefully dissecting the LV, it was embedded in formalin
(4%) for 24 hrs and afterwards in paraffin. 5 lm thick sections were
stained with hematoxilin/eosin and Masson’s trichrome. Fibrosis was
measured using a blinded counting system. For detection of apoptotic
nuclei, a terminal desoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) was used, allowing to identify DNA fragmentation.
Echocardiographic imaging
Transthoracic echocardiography was performed with a Vevo2100
imaging system (Visual Sonics, Toronto, ON, Canada) using a
40 MHz transducer. Therefore, mice were placed on a heating pad,
maintaining a body temperature of 37°C and providing ECG-triggered
analysis of heart function. After chemical depilation of the chest,
mice were prepared for echocardiography with ultrasound gel. Mice
were sedated with 2% isoflurane in 100% O2 at all times. Ejection
fraction (EF) was evaluated by planimetric measurement in the paras-
ternal long-axis (Simpson method). For evaluation of EF, three
consecutive cycles were measured and averaged. Diastolic thickness
of the LV posterior wall (LVPW) was measured in the parasternal
short-axis. The measurements were performed twice by two blinded
investigators.
Statistical analysis
Data are shown as mean  SEM. Multiple group comparison was per-
formed by one-way ANOVA followed by the Bonferroni procedure for com-
parison of means. Comparisons between two groups were performed
with the unpaired t-test. Analysis of survival was performed by the Kap-
lan–Meier method. Between-group difference in survival was tested with
the log-rank test. Values of P < 0.05 were considered statistically sig-
nificant.
Results
BMCs in hearts of mice with induced cardiac
hypertrophy
To analyse the influence of cardiac hypertrophy on migration of BMCs
(CD45+/CD34+ cells), we performed flow cytometry of a myocyte-
depleted fraction of cardiac cells. In mice with cardiac hypertrophy
the number of migrated CD45+ CD34+ VLA-4+ and CD45+ CD34+
c-kit+ cells was significantly increased compared to healthy control
mice (Fig. 1A and B), whereas the number of CD45+ CD34+ CXCR4+
A B
C
Fig. 1 Bone marrow-derived progenitor cells in the heart of healthy control mice (white bar), placebo treated mice with induced cardiac hypertrophy
(TAC + placebo, grey bar) and G-CSF treated mice with induced cardiac hypertrophy (TAC + G-CSF, black bar). (A) CD45+ CD34+ VLA-4+ cells.
(B) CD45+ CD34+ c-kit+ cells. (C) CD45+ CD34+ CXCR4+ cells. All cell populations are presented in % of mononuclear cells in the heart.
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cells showed no difference (Fig. 1C). G-CSF treatment in mice with
cardiac hypertrophy further markedly increased the number of
CD45+ CD34+ VLA-4+ cells (3.4-fold; P < 0.01) and CD45+ CD34+
c-kit+ cells (2.8-fold; P < 0.05; Fig. 1A and B). The number of




Fig. 2 Expression of homing factors in the heart of healthy control mice (white bar), placebo treated mice with induced cardiac hypertrophy (TAC +
placebo, grey bar), and G-CSF treated mice with induced cardiac hypertrophy (TAC + G-CSF, black bar). (A) mRNA expression levels of VCAM-1.
(B) mRNA expression levels of SCF. (C) mRNA expression levels of SDF-1.
A B
Fig. 3 Protein levels in the heart of healthy control mice (white bar), placebo treated mice with induced cardiac hypertrophy (TAC + placebo, grey
bar), and G-CSF treated mice with induced cardiac hypertrophy (TAC + G-CSF, black bar) analysed by ELISA. (A) Protein levels of VCAM-1. (B) Pro-
tein levels of SCF.
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Expression of myocardial homing factors in mice
with induced cardiac hypertrophy
To investigate potential migration pathways involved in cardiac hyper-
trophy, we analysed murine hearts for the expression of myocardial
homing factors (VCAM-1, SCF, SDF-1) interacting with the measured
subpopulations of BMCs using quantitative RT-PCR. The expression
levels of VCAM-1 (interacting with VLA-4) and SCF (interacting with
c-kit) were significantly up-regulated in mice with induced cardiac
hypertrophy compared to healthy controls (Fig. 2A and B). The
expression level of SDF-1 (interacting with CXCR4) showed no differ-
ence between mice with cardiac hypertrophy and healthy controls
(Fig. 2C). G-CSF treatment in mice with cardiac hypertrophy showed
a further increase of VCAM-1 and SCF, but without significance
(Fig. 2A and B). G-CSF treatment did not affect the expression levels
of SDF-1 (Fig. 2C).
Protein levels of VCAM-1 and SCF in mice with
induced cardiac hypertrophy
To confirm these findings, we analysed VCAM-1 and SCF on
protein levels using ELISA. VCAM-1 and SCF concentrations were
increased in mice with cardiac hypertrophy compared to healthy
control mice. G-CSF treatment showed a further increase in
protein levels of VCAM-1 and SCF in murine hearts (Fig. 3).
Impact of G-CSF therapy on myocardial fibrosis
and apoptosis in mice with cardiac hypertrophy
To visualize the impact of G-CSF on myocardial fibrosis and apoptosis
in cardiac hypertrophy, the murine hearts were analysed by histology.
The percentage of intramyocardial fibrosis of the LV was significantly
reduced in G-CSF treated mice (0.95  0.11% versus 2.13  0.30%;
P < 0.01; Fig. 4A). The fibrosis volume of the LV, expressed in mm3,
was also significantly reduced in G-CSF treated mice (2.67 
0.27 mm3 versus 5.67  1.02 mm3; P < 0.01; Fig. 4B and C). The
number of TUNEL-positive nuclei was reduced in G-CSF treated
mice (0.49  0.06 TUNEL+ cells/mm2, versus 0.74  0.09 TUNEL+
cells/mm2), although the difference was not significant (P < 0.07;
Fig. 4D).
Echocardiographic parameters in mice with
cardiac hypertrophy
Cardiac parameters were assessed by echocardiography before and




Fig. 4 Intramyocardial fibrosis and apoptosis in the LV analysed by histology in placebo treated mice with induced cardiac hypertrophy (TAC + placebo,
grey bar), and G-CSF treated mice with induced cardiac hypertrophy (TAC + G-CSF, black bar). (A) Fibrosis of the LV in %. (B) Fibrosis volume of the LV
in mm3. C Representative histological images of placebo treated mice (left) and G-CSF treated mice (right). (D) Number of TUNEL-positive cells/mm2.
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reduced in G-CSF treated mice compared to the control group
(26%; P < 0.05; Fig. 5A). EF in the G-CSF treated group decreased
by 2.37%  3.31% (Delta-EF concerning the difference of EF before
treatment and EF 4 weeks later). In contrast, EF in the control group
decreased by 12.85%  1.40% (Delta-EF; Fig. 5B and C).
Cumulative survival 4 weeks after initiation of
treatment
Cumulative survival of G-CSF as well as saline treated mice was
recorded for 4 weeks after initiation of treatment. Mortality increased
continuously throughout the recorded 4 weeks in both groups. How-
ever, G-CSF treated groups showed a significantly improved survival
(61.8% versus 79.2%; Fig. 6).
Discussion
In the present study, we wanted to investigate whether G-CSF is able
to attenuate cardiac hypertrophy and fibrosis in a mouse model of
pressure-induced LV hypertrophy induced by TAC. Our main findings
were the following: (i) G-CSF administration significantly increased
homing of VLA-4+ and c-kit+ BMCs to the hypertrophic heart after
TAC procedure. (ii) mRNA and Protein levels of VCAM-1- the ligand of
VLA-4 and SCF- the ligand of c-kit were increased after G-CSF stimu-
lation in the hypertrophic myocardium. (iii) G-CSF significantly
reduced the area of fibrosis compared to untreated controls. (iv)
Functionally, G-CSF significantly improved survival and preserved LV
function after TAC procedure.
In the last years, several studies focused on the endogenous
repair mechanisms after mobilization of BMCs by cytokines, like
G-CSF [9, 11, 18], parathyroid hormone [10, 13, 19, 20] or eryth-
ropoietin [21, 22] in ischaemic diseases like MI. It could be clearly
demonstrated that the interaction of SDF-1 with its ligand CXCR4
plays a major role in the migration of BMCs into ischaemic cardiac
tissue, which was associated with attenuated remodelling and
improved function [12, 23]. However, in non-ischaemic cardiomy-
opathies like DCM the interaction of SDF-1 with CXCR4 does not
seem to be the important driver of migration, because SDF-1
expression was not up-regulated in cardiac tissue of humans and
mice with DCM [16, 24].
In our study, G-CSF treatment after pressure-induced LV
hypertrophy significantly increased the amount of VLA-4+ and
c-kit+ BMCs in the heart, whereas the number of CXCR4+ BMCs
remained unchanged. In line with these results, we detected
increased mRNA and protein expression of two corresponding
homing factors VCAM-1 – the ligand of VLA-4 and SCF – the
ligand of c-kit in the hypertrophic heart. Recently, Brunner et al.
A B
C
Fig. 5 Echocardiographic results in placebo treated mice with induced cardiac hypertrophy (TAC + placebo, grey bar), and G-CSF treated mice with
induced cardiac hypertrophy (TAC + G-CSF, black bar). (A) Enddiastolic diameter of the LV posterior wall (LVPW d) after treatment with placebo or
G-CSF. (B) Difference of ejection fraction (EF) before and after treatment with placebo or G-CSF expressed as Delta EF. (C) Representative echocar-
diogram (M-mode) of mice after TAC procedure and treatment with placebo or G-CSF.
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were able to demonstrate in a murine model of virus-induced
DCM that G-CSF-induced VCAM-1/VLA-4 interaction is crucial for
the recruitment of circulating BMCs to the myocardium [24].
Notably, they could not detect increased numbers of c-kit+ or
enhanced expression of SCF, suggesting a different regulation of
cytokine profiles after DCM and pressure-induced LV hypertrophy.
In contrast to our findings, Szardien et al. did not detect signifi-
cant migration of BMCs 8 weeks after pressure unloading and
G-CSF treatment in mice. They used enhanced green fluorescent
protein (eGFP)-transgenic mice to track and distinguish the cells
of BM origin from sedentary cells in the myocardium [17]. How-
ever, two methodological differences might explain the different
findings. First, Szardien et al. did a debanding 8 weeks after TAC
procedure, which completely changes the cellular composition in
the myocardium compared to a chronic pressure overload [25].
Secondly, they did histological analyses 2 weeks after G-CSF puls-
ing to evaluate a numerical difference in eGFP+ cells between
study groups. According to previous studies the maximum of
mobilization and homing of BMCs occurs early after cytokine
treatment [11]. Therefore, they might have missed the peak of cell
infiltration within the myocardium.
In accordance with the functional data from Szardien et al.,
we found a significant preservation of LV function after G-CSF
treatment compared to controls. Histologically, there was an
attenuated cardiac remodelling reflected by diminished amount of
fibrosis. VCAM-1 has been shown to be involved in inflammatory
Fig. 7 Suggested mechanism of G-CSF-
mediated cardioprotection after TAC-
induced hypertropy. G-CSF administration
after TAC induces mobilization of stem
cells from the BM to the peripheral blood.
These stem cells migrate to the hypertro-
phic heart via the VLA-4/VCAM-1 and c-
kit/SCF axes. The interaction of SDF-1
with CXCR4 seems not to be involved in
this process.
Fig. 6 Cumulative survival of placebo trea-
ted mice with induced cardiac hypertrophy
(TAC + placebo), and G-CSF treated mice
with induced cardiac hypertrophy (TAC +
G-CSF).
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processes. Recently, it has been demonstrated that VCAM-1/VLA-
4 signalling exerts cardioprotective effects through enhanced
angiogenesis [26] as well as facilitating survival of cardiomyo-
cytes by activation of Akt, ERK and p38 MAPK [27]. Likewise,
G-CSF treatment was able to increase the expression of myocar-
dial anti-apoptotic proteins and decreased TUNEL+ nuclei after MI
[28]. In this regard, we were interested whether G-CSF affects
apoptosis after TAC-induced hypertrophy. Histological analysis of
the hypertrophic LV revealed a decreased number of TUNEL+
cells reflecting a trend towards diminished apoptosis after G-CSF
treatment. Our data also indicate an important role for c-kit+
cells, which are attracted by increased SCF protein levels in
hypertrophic hearts after G-CSF injections. Fazel et al. were able
to demonstrate that MI increased the number of c-kit+ cells in
ischaemic hearts. They used genetic tagging in bone marrow chi-
meric mice to track these cells back to a bone marrow origin.
Intriguingly, the recruited c-kit+cells established a pro-angiogenic
milieu in the infarct border zone by increasing VEGF and by
reversing the cardiac ratio of angiopoietin-1 to angiopoietin-2
[29]. In this regard, SCF significantly increased matrix metallo-
proteinases (MMP-2 and MMP-9) mRNA in mouse liver cells
[30]. Szardien et al. demonstrated that the G-CSF induced degra-
dation of ECM in their model of pressure unloading was caused
by an increased activity of both MMP-2 and MMP-9, both physi-
ological enzymes with collagen-degrading properties [31].
In summary, our findings suggest a novel role of G-CSF in
regressing fibrosis and preventing heart failure in pressure-induced
cardiac hypertrophy, because of the modulation of cardiac cytokine
profiles, which attract beneficial VLA-4+ and c-kit+ BMCs (Fig. 7).
However, it will be the goal of further studies to establish a direct link
between cell migration and attenuation of cardiac remodelling after
G-CSF treatment in hypertrophic hearts.
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